George Shultz Innovation Fund Awards $250K to Parasol Med Tech
The University of Chicago's Polsky Center announced a $250,000 investment in Parasol MedTech through the George Shultz Innovation Fund.
Parasol MedTech is developing an integrated catheter-and-gel system designed to adapt to the unique anatomy of the left atrial appendage—with the goal of eliminating the need for a permanent metal implant.
No two left atrial appendages are the same. Each has its own shape, size, depth, lobes, and internal geometry. Yet today’s closure technologies rely on permanent metallic implants with predetermined shapes and sizes.
For complex appendages, fitting a fixed mechanical structure to highly variable anatomy can create challenges with device selection, positioning, sealing, and fixation. And despite advances in LAA closure, residual leak, device-related thrombus, stroke, and bleeding remain important clinical concerns.
Every LAA presents a unique three-dimensional geometry.
Traditional devices rely on predetermined shapes and sizes with permanent mechanical fixation.
Parasol is developing an integrated catheter-and-gel platform that combines temporary structural control with anatomy-driven gel delivery. Parasol’s device is investigational and has not been cleared or approved by the FDA.
Parasol’s investigational platform combines temporary mechanical control with targeted gel delivery in a single integrated catheter system—designed to enable precise, anatomy-driven LAA closure.
After performing more than 1,000 left atrial appendage closure procedures, Dr. Atman Shah recognized a fundamental limitation of existing technology: fixed mechanical implants must fit highly variable anatomy.
Parasol was born from a different idea—an integrated catheter-and-gel platform designed to adapt to each patient’s unique anatomy.
Atman P. Shah, MD, FSCAI, FACC
Founder & Chief Medical Officer
The University of Chicago's Polsky Center announced a $250,000 investment in Parasol MedTech through the George Shultz Innovation Fund.
Dr. Atman Shah discusses the clinical rationale behind Parasol MedTech's investigational left atrial appendage closure platform in an interview with EP Lab Digest.
Cardiovascular Business covers Dr. Atman Shah's investigational catheter-and-gel approach to left atrial appendage closure and its early development through Parasol MedTech.
Connect with the Parasol Med Tech team to learn more about our investigational left atrial appendage closure platform and development efforts.
Parasol MedTech is developing an integrated catheter-and-gel platform designed to adapt to variable left atrial appendage anatomy. Parasol’s device is investigational and has not been cleared or approved by the FDA.
5207 South Harper Avenue
Suite 500
Chicago, IL 60615
Copyright © 2026 Parasol Med Tech, Inc. All rights reserved.